Resumen De Ascrs 2010

OphthalmologyWeb Community
Comment
All Comments
Featured Articles
All Articles
Print
Email Article .This year the ASCRS meeting was held in conjunction with the World Cornea Congress inBoston. With speakers from throughout the US and abroad, new ideas were exchanges for improving clinical and surgical outcomes, and new technologies were also displayed for the first time. This articlereviews many of these exciting developments.

In the pharmaceutical arena, Dr. Eric Donnenfeld presented data comparing cataract surgery patients treated with prednisolone acetate or difluprednate(Durezol, Sirion now acquired by Alcon). While dosing regimens were the same between both patient populations, those treated with difluprednate had significantly better vision and thinner cornealpachymetry on postoperative day #1. While this was more of an immediate benefit and two weeks out vision was equivalent, he also found that patients treated with difluprednate at 30 days post-op hadsignificantly higher endothelial cell counts and significant thinner maculas. While seemingly excellent in improving cataract surgery outcomes,Drs. Ed Holland and William Trattler touted the benefits ofthis stronger steroid for enhancing corneal and pterygium surgeries as well.

Another advance that may greatly improve surgical outcomes is the release of ocular sealants. Designed to be verybiocompatible, these offer the ability to more securely close wounds and expedite recovery times. Dr. Steven Dell presented his experience on the ReSure Ocular Bandage (Ocular Therapeutix, Inc., Bedford, MA)and noted that it was well tolerated by his patients. Additional future options for this technology include I-Zip Ocular Bandage (I-Therapeutix, Inc) and the Ocuseal Liquid Ocular Bandage (Becton,Dickinson and Company).

Early US clinical results with improved surgical devices were also presented, particularly the Tan Endoglide (watch video) for use with Descemet Striping Endothelial...